Related Experiment Videos
[Cladribine].
1Dept. of Hematology and Chemotherapy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 4, 2003
Summary
Cladribine (2-chlorodeoxyadenosine: 2-CdA) effectively treats indolent lymphoid malignancies like hairy cell leukemia. Its unique mechanism targets lymphocytes, leading to cell death, independent of cell division.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Context:
- Cladribine (2-chlorodeoxyadenosine: 2-CdA) is a purine analogue resistant to adenosine deaminase.
- Its phosphorylated form targets lymphocytes with high deoxycytidine kinase activity.
- This mechanism induces DNA strand breaks and cell death.
Purpose:
- To evaluate the efficacy, toxicity, and clinical utility of cladribine.
- To assess its suitability for treating indolent lymphoid malignancies.
- To review clinical trial data from the US, Europe, and Japan.
Summary:
- Cladribine's cytotoxic effects are independent of cell division, making it suitable for low-growth fraction malignancies.
- The FDA approved cladribine for hairy cell leukemia in 1993.
- Japan approved cladribine (Leustatin) for hairy cell leukemia and indolent B-cell lymphoma in 2002.
Impact:
- Cladribine demonstrates significant efficacy in treating specific lymphoid cancers.
- Clinical trials confirm its therapeutic value and inform treatment protocols.
- This research supports cladribine's role in managing indolent lymphoid malignancies.